- Buparlisib
-
- $57.00 / 5mg
-
2024-11-19
- CAS:944396-07-0
- Min. Order:
- Purity: 98.4%
- Supply Ability: 10g
- NVP-BKM-120
-
- $0.00 / 1gram
-
2022-02-18
- CAS:944396-07-0
- Min. Order: 1gram
- Purity: 99%
- Supply Ability: 10kg
|
| | BKM120 (NVP-BKM120, Buparlisib) Basic information |
| | BKM120 (NVP-BKM120, Buparlisib) Chemical Properties |
| Melting point | 143-147°C | | Boiling point | 645.7±65.0 °C(Predicted) | | density | 1.382 | | storage temp. | -20°C | | solubility | Soluble in DMSO (15 mg/ml) | | form | White powder. | | pka | 5.94±0.50(Predicted) | | color | White | | Stability: | Stable for 1 year as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. |
| | BKM120 (NVP-BKM120, Buparlisib) Usage And Synthesis |
| Description | Buparlisib (944396-07-0) is potent pan-Class I PI3-kinase inhibitor (IC50’s: p110α = 52 nM, p110? = 166 nM, p110δ = 116 nM. P110g = 262 nM).1,2 It inhibited microtubule dynamics at in vitro concentrations >1μM and doses above 50mg/kg in mice.3 Buparlisib lead to a precipitous drop in DNA synthesis in a mouse model of BRCA1-linked triple-negative breast cancer with less affect in normal tissue.4 | | Uses | A selective Class I PI3K inhibitor of p110α, p110β, p110δ and p110γ with IC50s of 50-300 nM. | | Uses | NVP-BKM 120 is a novel anti-tumor active compound that is selective in that it inhibits specifically PI3 kinase activating cell death in glioma cells. Glioma cells being those that proliferate from tumors in the brain or the spine. | | Definition | ChEBI: BKM120 is an aminopyridine that is 4-(trifluoromethyl)pyridin-2-amine substituted at position 5 by a 2,6-di(morpholin-4-yl)pyrimidin-4-y group. A selective PI3K inhibitor with anti-tumour properties. It has a role as an EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor and an antineoplastic agent. It is a member of morpholines, an aminopyrimidine, an aminopyridine and an organofluorine compound. | | target | p110α | | References | Burger et al. (2011), Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer; ACS Med. Chem. Lett. 2 774
Maira et al. (2012), Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor; Mol. Cancer Ther. 11 317
Brachmann et al. (2012), Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations; Mol. Cancer Ther. 11 1747
Juvekar et al. (2016), Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion; Proc. Natl. Acad. Sci USA. 113 E4338 |
| | BKM120 (NVP-BKM120, Buparlisib) Preparation Products And Raw materials |
|